Type of ALL-B-lymphoblastic leukemia/lymphoma Posts on Medivizor
Navigation Menu

Type of ALL-B-lymphoblastic leukemia/lymphoma Posts on Medivizor

The effects of blinatumomab in patients with relapsed or unresponsive acute lymphoblastic leukemia in outside of clinical trials

Posted by on Feb 24, 2020 in Leukemia | 0 comments

In a nutshell The study evaluated the safety and effectiveness of blinatumomab (Blincyto) in patients with relapsed or unresponsive B-acute lymphoblastic leukemia (B-ALL) outside of clinical trials. The authors found that blinatumomab was safe and effective to treat such patients in real-world medical practice. Some background Relapsed...

Read More

The effects of blinatumomab therapy in patients with relapsed/refractory acute lymphoblastic leukemia before transplantation

Posted by on Feb 19, 2020 in Leukemia | 0 comments

In a nutshell The study investigated whether blinatumomab (Blincyto) can be used for salvage therapy before hematopoietic cell transplantation (HCT) in patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL). The main finding was that blinatumomab can be safely and effectively used in patients with r/r B-ALL before HCT. Some...

Read More

Minimal residual disease response leading to better outcomes for patients with relapsed/refractory acute lymphoblastic leukemia after treatment with blinatumomab

Posted by on Dec 7, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to evaluate the relationship between minimal residual disease response and outcomes in patients with relapsed/unresponsive B-cell precursor acute lymphoblastic leukemia who were treated with blinatumomab.   This study concluded that achieving minimal residual disease response leads to better outcomes for...

Read More

Stem cell transplant after blinatumomab in patients with relapsed or unresponsive acute lymphoblastic leukemia

Posted by on Sep 13, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the outcomes for patients who underwent allogeneic hematopoietic stem cell transplant after treatment with blinatumomab.  This study concluded that survival was driven by the response to study treatment and by salvage status regardless of transplant status.   Some...

Read More

Inotuzumab ozogamicin for patients with relapsed/unresponsive acute lymphoblastic leukemia

Posted by on Apr 24, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the long-term safety and effectiveness of inotuzumab ozogamicin (Besponsa) for patients with relapsed or unresponsive acute lymphoblastic leukemia.   This study concluded that this treatment was safe and effective for these patients. Some background Inotuzumab ozogamicin (InO) is a targeted...

Read More

Looking for young patients with B-cell acute lymphoblastic leukemia to test a new T-cell therapy

Posted by on Apr 22, 2019 in Leukemia | 0 comments

In a nutshell This phase 2 trial is evaluating the effectiveness of huCART19 cell therapy in young patients with high-risk B-cell acute lymphoblastic leukemia (ALL). The main outcome to be measured will be survival without a treatment-related complication. This study is being conducted in Philadelphia, Pennsylvania, United States. The details Acute...

Read More

CAR-T cell therapy and infection risk

Posted by on Dec 16, 2017 in Leukemia | 0 comments

In a nutshell This study examined infection risk in leukemia and lymphoma patients treated with CAR-T cell therapy, a new type of immunotherapy. Researchers reported that infection rates were comparable to other salvage therapies.  Some background Chimeric antigen receptor (CAR) T-cell therapy helps the immune system to fight cancer cells. In...

Read More

CAR-T cell therapy and infection risk

Posted by on Dec 16, 2017 in Leukemia | 0 comments

In a nutshell This study examined infection risk in leukemia and lymphoma patients treated with CAR-T cell therapy, a new type of immunotherapy. Researchers reported that infection rates were comparable to other salvage therapies.  Some background Chimeric antigen receptor (CAR) T-cell therapy helps the immune system to fight cancer cells. In...

Read More

Blinatumomab: A new monoclonal antibody therapy as a treatment option for relapsed B-cell ALL

Posted by on Mar 21, 2017 in Leukemia | 0 comments

In a nutshell This study examined remission rates with blinatumomab (Blincyto) treatment in patients with relapsed adult acute lymphoblastic leukemia (ALL). Researchers concluded that blinatumomab can achieve complete remission in patients with unfavorable ALL. However, this was an early-phase trial and more studies are needed. Some background...

Read More